The €200M licensing deal that destroyed a €2B biotech

The CEO was literally ringing the opening bell at NASDAQ.

Cameras flashed. Investors cheered. The European biotech had just announced a €200M licensing deal with a major pharmaceutical partner.

The stock jumped 40 per cent before lunch. By market close, the company had added €800M in market capitalisation.

Eighteen months later, that same CEO was being sued by the investors who had celebrated with him. The company would eventually be sold for parts at an 80 per cent discount to its peak valuation.

What happened? A licensing deal — announced with champagne and fanfare — concealed a balance sheet time bomb that was ticking from day one.

This is the story nobody tells you about "transformational" deals.

The deal that looked perfect

The structure that seemed so promising

The announcement:

• Total deal value: €200M
• Upfront payment: €30M
• Development milestones: €70M
• Commercial milestones: €100M
• Royalties: mid-single digits on net sales

The market loved it. Seven analyst firms raised their price targets. Every major biotech publication covered the announcement.

But the finance team was notably quiet. That should have been the first warning sign.

Behind the scenes

The capitalisation time bomb

The licensing deal required massive ongoing development work. Additional preclinical studies (€35M), manufacturing scale-up (€45M), regulatory preparation (€15M), and ongoing technical support (€25M) added up to €120M of investment over 18 to 24 months.

The company's accounting policy allowed them to capitalise these development costs as intangible assets on the balance sheet, but only if future economic benefits were "probable."

So the finance team built their capitalisation model on assumptions provided by the business development team.

They capitalised €120M in development costs based on these assumptions.

Then reality hit

Phase III setback, and the audit conclusion

Eighteen months after the deal closed, the partner announced regulatory delays in their quarterly earnings call. A six-month Phase III trial setback. The FDA requested additional studies. Peak sales projections revised down 50 per cent to €400M. New timeline to approval: 42 months or more.

The company's external auditors immediately reviewed the €120M in capitalised development costs against the new projections. Their conclusion: the assets should be impaired.

The Friday afternoon press release

What came next destroyed the company

Three class-action lawsuits filed within ten days. Emergency financing at a 60 per cent discount to prior valuation. Existing shareholders diluted by 45 per cent.

Why this keeps happening

Institutional incentives, not malicious intent

Business development wants to close deals (bonuses tied to deal value), optimistic projections (support deal rationale), and minimal complexity (accelerate signing).

Finance needs conservative assumptions (audit defensibility), realistic timelines (capitalisation justification), and detailed contingency planning (risk management).

When BD drives the bus and finance sits in the back, you get €120M in capitalised assets built on wishful thinking.

The warning signs everyone missed

Three moments the deal could have been saved

• Month 3. Finance sent a memo to the board expressing concern about the capitalisation assumptions and recommending more conservative projections. The response: "Don't be so conservative. This is a game-changing deal." Finance was overruled.
• Month 9. The external auditors questioned the 85 per cent probability of regulatory success, noting it was significantly higher than industry averages of 45 to 55 per cent. Management provided a memo from BD citing "partner's strong track record" and "differentiated mechanism." The auditors noted their concerns but did not push harder.
• Month 11. When auditors continued raising questions, the company requested proposals from other audit firms "to ensure best service and value." Translation: find us auditors who will be more flexible.

The original sin

Finance was not in the room

The most damning fact: the CFO was not involved in structuring the deal. The negotiating team was BD, legal, and R&D. Finance saw the term sheet and provided feedback. The next thing they knew, the deal had been signed, without finance ever seeing the draft contract before signatures.

By then, the structure was locked in — capitalisation time bomb included.

The one question

What could have saved the deal

The honest answer would have been: "We would face a €50–95M impairment charge."

That answer would have forced one of three outcomes — restructure the deal to reduce upfront investment requirements, change accounting policy to expense costs as incurred, or walk away from a deal with unacceptable balance sheet risk. Any of those would have been better than what actually happened.

Your action items this week

If you are evaluating a licensing deal right now

• Bring your CFO into deal discussions before the term sheet is signed.
• Ask: "What costs will we capitalise, and what assumptions are they built on?"
• Model the impairment risk: "What if timelines slip by six months? Twelve months?"
• Engage your auditors before signing, not after.
• Demand multiple scenario analysis (base, downside, worst-case).

If you signed a deal in the past 24 months

• Review your capitalised development costs against current projections.
• Assess whether original assumptions still hold.
• Model potential impairment exposure.
• Consider voluntary disclosure if material gaps exist.

Coming next

The hidden liabilities that sink licensing deals

This was just one of three balance sheet time bombs hiding in licensing deals. The next article in the series examines minimum royalty guarantees, earn-outs, and working capital mismatches — how contingent obligations turn profitable deals into cash drains.

Read Article 2 →